These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3283628)

  • 1. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial.
    Beelen DW; Graeven U; Schulz G; Grosse-Wilde H; Doxiadis I; Schaefer UW; Quabeck K; Sayer H; Schmidt CG
    Onkologie; 1988 Feb; 11(1):56-8. PubMed ID: 3283628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor.
    Beelen DW; Grosse-Wilde H; Ryschka U; Quabeck K; Sayer HG; Graeven U; Schaefer UW
    Cancer Immunol Immunother; 1991; 34(2):97-102. PubMed ID: 1836976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment.
    Hiscott A; McLellan DS
    Br J Biomed Sci; 2000; 57(2):163-9. PubMed ID: 10912294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.
    Wawer A; Laws HJ; Dilloo D; Göbel U; Burdach S
    Klin Padiatr; 2004; 216(3):169-75. PubMed ID: 15175962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease.
    Anasetti C; Martin PJ; Hansen JA; Appelbaum FR; Beatty PG; Doney K; Harkonen S; Jackson A; Reichert T; Stewart P
    Transplantation; 1990 Jul; 50(1):49-54. PubMed ID: 2368150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
    Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
    JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes.
    Gratama JW; Jansen J; Lipovich RA; Tanke HJ; Goldstein G; Zwaan FE
    Transplantation; 1984 Nov; 38(5):469-74. PubMed ID: 6388068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients.
    Herve P
    J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD; McCabe C; Hanke CA; Truitt RL
    J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.